MIRA Pharmaceuticals (NASDAQ:MIRA) Trading Down 1.3% – Here’s What Happened

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)’s share price dropped 1.3% during trading on Friday . The stock traded as low as $0.9810 and last traded at $0.9870. Approximately 76,948 shares were traded during trading, a decline of 48% from the average daily volume of 147,977 shares. The stock had previously closed at $1.00.

Wall Street Analysts Forecast Growth

MIRA has been the subject of several analyst reports. Rodman & Renshaw initiated coverage on MIRA Pharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a research note on Friday, March 27th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, MIRA Pharmaceuticals presently has a consensus rating of “Hold”.

MIRA Pharmaceuticals Stock Down 1.3%

The company has a market cap of $41.47 million, a price-to-earnings ratio of -0.65 and a beta of 1.48. The company has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $1.31.

Institutional Trading of MIRA Pharmaceuticals

Several large investors have recently bought and sold shares of MIRA. XTX Topco Ltd acquired a new stake in MIRA Pharmaceuticals in the second quarter valued at $26,000. Creative Planning acquired a new stake in shares of MIRA Pharmaceuticals during the second quarter valued at $27,000. Fifth Third Bancorp acquired a new stake in shares of MIRA Pharmaceuticals during the fourth quarter valued at $30,000. Two Sigma Investments LP boosted its stake in shares of MIRA Pharmaceuticals by 129.8% during the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares during the last quarter. Finally, First American Bank boosted its stake in shares of MIRA Pharmaceuticals by 20.0% during the fourth quarter. First American Bank now owns 60,000 shares of the company’s stock valued at $91,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors and hedge funds own 35.16% of the company’s stock.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.